Joana Camões Neves1,2, João Sérgio Neves3,4,5,6, Celestino Neves3,4,6, Davide Carvalho3,4,6. 1. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal. joanacamoesneves@gmail.com. 2. Faculty of Medicine, University of Porto, Porto, Portugal. joanacamoesneves@gmail.com. 3. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal. 4. Faculty of Medicine, University of Porto, Porto, Portugal. 5. Department of Surgery and Physiology, Cardiovascular Research Unit, Faculty of Medicine, University of Porto, Porto, Portugal. 6. Institute for Research and Innovation in Health Sciences, University of Porto, Porto, Portugal.
Abstract
PURPOSE: Insulin pump therapy has become the preferential treatment for type 1 diabetes (T1D) as it mimics the physiological secretion of insulin better than multiple daily injections. However, not all patients improve with insulin pump therapy. This study aims to determine the predictors of the effectiveness of insulin pumps in T1D. METHODS: We conducted a retrospective observational study of patients who started insulin pumps. Data from four timepoints (before, at 6, 12, and 36 months) were evaluated for outcomes of glycemic control and safety. The association of baseline predictors with outcomes was analyzed using linear and logistic regression models. RESULTS: We evaluated 136 patients (57.4% females, age 36 ± 12 years, duration of T1D 14 ± 9 years). During the follow-up, there was a mean decrease of HbA1c of 0.9 ± 1.2%. The improvement in HbA1c was independent of sex, age, and duration of T1D. Higher baseline HbA1c, family history of diabetes, and not being treated with statins were predictors of improvement in HbA1c. Not being treated with statins and higher baseline HbA1c predicted improvement in HbA1c without worsening hypoglycemia. History of hypoglycemia was a predictor of severe hypoglycemia. Family history, higher baseline HbA1c, and psychological/psychiatric disorders were predictors of ketoacidosis. CONCLUSION: Benefits of insulin pump were independent of sex, age, and duration of T1D. Baseline HbA1c, family history of diabetes, treatment with statins, history of hypoglycemia, and psychological/psychiatric disorders were predictors of outcomes, and may allow the identification of patients who benefit most from insulin pump therapy or who are at increased risk of complications.
PURPOSE: Insulin pump therapy has become the preferential treatment for type 1 diabetes (T1D) as it mimics the physiological secretion of insulin better than multiple daily injections. However, not all patients improve with insulin pump therapy. This study aims to determine the predictors of the effectiveness of insulin pumps in T1D. METHODS: We conducted a retrospective observational study of patients who started insulin pumps. Data from four timepoints (before, at 6, 12, and 36 months) were evaluated for outcomes of glycemic control and safety. The association of baseline predictors with outcomes was analyzed using linear and logistic regression models. RESULTS: We evaluated 136 patients (57.4% females, age 36 ± 12 years, duration of T1D 14 ± 9 years). During the follow-up, there was a mean decrease of HbA1c of 0.9 ± 1.2%. The improvement in HbA1c was independent of sex, age, and duration of T1D. Higher baseline HbA1c, family history of diabetes, and not being treated with statins were predictors of improvement in HbA1c. Not being treated with statins and higher baseline HbA1c predicted improvement in HbA1c without worsening hypoglycemia. History of hypoglycemia was a predictor of severe hypoglycemia. Family history, higher baseline HbA1c, and psychological/psychiatric disorders were predictors of ketoacidosis. CONCLUSION: Benefits of insulin pump were independent of sex, age, and duration of T1D. Baseline HbA1c, family history of diabetes, treatment with statins, history of hypoglycemia, and psychological/psychiatric disorders were predictors of outcomes, and may allow the identification of patients who benefit most from insulin pump therapy or who are at increased risk of complications.
Authors: Sheri R Colberg; Ronald J Sigal; Jane E Yardley; Michael C Riddell; David W Dunstan; Paddy C Dempsey; Edward S Horton; Kristin Castorino; Deborah F Tate Journal: Diabetes Care Date: 2016-11 Impact factor: 19.112
Authors: Rajit A Gilhotra; Beverly T Rodrigues; Venkat N Vangaveti; George Kan; David Porter; Kunwarjit S Sangla; Usman H Malabu Journal: Ren Fail Date: 2016-06-08 Impact factor: 2.606
Authors: Beate Karges; Anke Schwandt; Bettina Heidtmann; Olga Kordonouri; Elisabeth Binder; Ulrike Schierloh; Claudia Boettcher; Thomas Kapellen; Joachim Rosenbauer; Reinhard W Holl Journal: JAMA Date: 2017-10-10 Impact factor: 56.272
Authors: David M Nathan; Bernard Zinman; Patricia A Cleary; Jye-Yu C Backlund; Saul Genuth; Rachel Miller; Trevor J Orchard Journal: Arch Intern Med Date: 2009-07-27
Authors: Emma S Scott; Rachel T McGrath; Andrzej S Januszewski; Daniel Calandro; Anandwardhan A Hardikar; David N O'Neal; Gregory Fulcher; Alicia J Jenkins Journal: BMJ Open Date: 2019-12-29 Impact factor: 2.692